Vivos Therapeutics (VVOS) Current Leases (2021 - 2026)

Vivos Therapeutics (VVOS) has reported Current Leases for 6 consecutive years, with $790000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Leases rose 20.8% year-over-year to $790000.0 in Q2 2026; TTM through Jun 2026 was $790000.0, a 20.8% increase from a year earlier, with the FY2025 full-year figure at $672000.0, up 40.88% from the prior year.
• Current Leases was $790000.0 for Q2 2026 at Vivos Therapeutics, up from $744000.0 in the prior quarter.
• Over five years, Current Leases peaked at $790000.0 in Q2 2026 and troughed at $357000.0 in Q1 2022.
• A 5-year average of $522722.2 and a median of $475500.0 in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases soared 481.94% in 2022 and slipped 3.31% in 2025, its largest moves.
• Over 5 years, Current Leases stood at $419000.0 in 2022, then rose by 13.13% to $474000.0 in 2023, then gained by 0.63% to $477000.0 in 2024, then surged by 40.88% to $672000.0 in 2025, then gained by 17.56% to $790000.0 in 2026.
• The last three Current Leases figures came in at $790000.0 (Q2 2026), $744000.0 (Q1 2026), and $672000.0 (Q4 2025), per Business Quant data.